cerecor inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. we are a delaware corporation, organized in april 2011 in partnership with various laboratories and research institutes at johns hopkins medical institute ("jhmi"). cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. we acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.
Company profile
Ticker
AVTX
Exchange
Website
CEO
Michael F. Cola
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cerecor Inc.
SEC CIK
Corporate docs
Subsidiaries
Medgenics Medical (Israel) Ltd. • Aevi Genomic Medicine Europe ...
AVTX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
28 Mar 24
8-K
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
28 Mar 24
8-K
Other Events
31 Jan 24
8-K
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
28 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
20 Dec 23
DEFA14A
Additional proxy soliciting materials
7 Dec 23
8-K
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
7 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
Latest ownership filings
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
4
Magnus Persson
21 Dec 23
4
June Sherie Almenoff
21 Dec 23
4
GILLA KAPLAN
21 Dec 23
4
Mitchell Chan
21 Dec 23
4
Magnus Persson
5 Jul 23
4
June Sherie Almenoff
5 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.31 mm | 10.31 mm | 10.31 mm | 10.31 mm | 10.31 mm | 10.31 mm |
Cash burn (monthly) | (no burn) | 572.08 k | 1.74 mm | 2.68 mm | 2.28 mm | 2.65 mm |
Cash used (since last report) | n/a | 3.42 mm | 10.41 mm | 16.06 mm | 13.64 mm | 15.88 mm |
Cash remaining | n/a | 6.89 mm | -100.32 k | -5.75 mm | -3.32 mm | -5.57 mm |
Runway (months of cash) | n/a | 12.0 | -0.1 | -2.1 | -1.5 | -2.1 |
Institutional ownership, Q2 2023
2.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 5 |
Closed positions | 10 |
Increased positions | 7 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 847.71 mm |
Total shares | 4.37 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Venrock Healthcare Capital Partners III | 1.35 mm | $4.68 mm |
VR Adviser | 1.25 mm | $444.00 mm |
Armistice Capital | 588.85 k | $294.00 k |
Nantahala Capital Management | 556.20 k | $197.56 mm |
Vanguard | 222.07 k | $78.88 mm |
BLK Blackrock | 124.45 k | $44.20 mm |
Geode Capital Management | 80.97 k | $28.76 mm |
Millennium Management | 33.93 k | $12.05 mm |
VIRT Virtu Financial | 32.59 k | $12.00 k |
STT State Street | 25.64 k | $9.11 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Dec 23 | June Sherie Almenoff | Stock Option Common Stock | Grant | Acquire A | No | No | 0.043 | 3,334 | 143.36 | 3,334 |
20 Dec 23 | Mitchell Chan | Stock Option Common Stock | Grant | Acquire A | No | No | 0.043 | 3,334 | 143.36 | 3,334 |
20 Dec 23 | Gilla Kaplan | Stock Option Common Stock | Grant | Acquire A | No | No | 0.043 | 3,334 | 143.36 | 3,334 |
20 Dec 23 | Persson Magnus | Stock Option Common Stock | Grant | Acquire A | No | No | 0.043 | 3,334 | 143.36 | 3,334 |
26 Jun 23 | Caissa Capital Management | Common Stock | Buy | Dispose P | No | No | 0.62 | 182,300 | 113.03 k | 0 |
26 Jun 23 | Caissa Capital Management | Common Stock | Buy | Dispose P | Yes | No | 0.6433 | 1,425,700 | 917.15 k | 0 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Mar 24
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
28 Mar 24
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
28 Mar 24
Gold Gains 1%; Walgreens Narrows Earnings Forecast
28 Mar 24